About: Implications of ABO blood group in hypertensive patients with covid-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Implications of ABO blood group in hypertensive patients with covid-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Implications of ABO blood group in hypertensive patients with covid-19
Creator	Cirillo, Paolo Gambardella, Jessica Maggi, Paolo Marfella, Raffaele Messina, Vincenzo Paolisso, Giuseppe Santulli, Gaetano Sardu, Antonio Sardu, Celestino Vanvitelli, Luigi Caserta, Locale Sanitaria, Azienda
Source	Medline; PMC
abstract	Background: Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a specific blood group could play a key role in the clinical outcome of hypertensive patients with covid-19. Methods : In this prospective study, we compared 0 vs. non-0 blood group in hypertensive patients with covid-19 infection. In these patients, we evaluated inflammatory and thrombotic status, cardiac injury, and death events. Results: Patients in non-0 (n=92) vs. 0 blood group (n=72) had significantly different values of activated pro-thrombin time, D-dimer, and thrombotic indexes as Von Willebrand factor and Factor VIII (p<0.05). Furthermore, patients in non-0 vs. 0 blood group had higher rate of cardiac injury (10 (13.9%) vs. 27 (29.3%)) and death, (6 (8.3%) vs. 18 (19.6%)), (p <0.05). At the multivariate analysis, Interleukin-6 (1.118, CI 95% 1.067-1.171) and non-0 blood group (2.574, CI 95% 1.207-5.490) were independent predictors of cardiac injury in hypertensive patients with covid-19. D-dimer (1.082, CI 95% 1.027-1.140), Interleukin-6 (1.216, CI 95% 1.082-1.367) and non-0 blood group (3.706, CI 95% 1.223-11.235) were independent predictors of deaths events in hypertensive patients with covid-19. Conclusions : Taken together, our data indicate that non-0 covid-19 hypertensive patients have significantly higher values of pro-thrombotic indexes, as well as higher rate of cardiac injury and deaths compared to 0 patients. Moreover, AB0 blood type influences worse prognosis in hypertensive patients with covid-19 infection.
has issue date	2020-08-12(xsd:dateTime)
bibo:doi	10.21203/rs.3.rs-28258/v2
bibo:pmid	32818207
has license	cc-by
sha1sum (hex)	70abf368c768e380d6cb5bb76ca7c90aff5e4fcb
schema:url	https://doi.org/10.21203/rs.3.rs-28258/v2
resource representing a document's title	Implications of ABO blood group in hypertensive patients with covid-19
has PubMed Central identifier	PMC7430579
has PubMed identifier	32818207
schema:publication	Res Sq
resource representing a document's body	covid:70abf368c768e380d6cb5bb76ca7c90aff5e4fcb#body_text
is schema:about of	named entity 'PLAY' named entity 'covid-19' named entity 'blood group' named entity 'hypertensive' named entity 'hypertensive' named entity 'polymorphism' named entity 'invasive ventilation' named entity 'covid-19' named entity 'blood group' named entity 'speci' named entity 'tocilizumab' named entity 'D-dimer' named entity 'adverse events' named entity 'respiratory failure' named entity 'dyslipidemia' named entity 'endothelial dysfunction' named entity 'blood group' named entity 'thrombotic complications' named entity 'medical charts' named entity 'heart diseases' named entity 'thrombosis' named entity 'blood group' named entity 'genetic susceptibility' named entity 'AB0' named entity 'blood group' named entity 'co-factor' named entity 'organ failure' named entity 'survival analysis' named entity 'medical therapy' named entity 'C.S' named entity 'ethics committee' named entity 'prognosis' named entity 'ARB' named entity 'myocardial injury' named entity 'Von Willebrand factor' named entity 'EDTA' named entity 'blood group' named entity 'genetic variations' named entity 'body mass index' named entity 'critically ill' named entity 'high-risk' named entity 'electrolytes' named entity 'P.M' named entity 'respiratory syncytial virus' named entity 'blood group' named entity 'pneumonia' named entity 'C-reactive protein' named entity 'viral infections' named entity 'co-morbidity' named entity 'high density lipoprotein' named entity 'SARS-CoV-2' named entity 'R506Q' named entity 'covid-19' named entity 'covid-19' named entity 'locus' named entity 'covid-19' named entity 'blood group' named entity 'hypertension' named entity 'assay' named entity 'troponin' named entity 'coagulative' named entity 'covid-19' named entity 'blood group' named entity 'negative correlation' named entity 'reference limit' named entity 'aspirin' named entity 'D-dimer' named entity 'serum levels' named entity 'thrombosis' named entity 'study population'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software